$KNSA insider trading
Over the last 12 months, Kiniksa Pharmaceuticals International insiders reported no purchases and 29 sales totaling $61.9M across SEC Form 4 filings. 97% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $61.9M 29 events
- Events · 12m
- 29 Form 4 filings, grouped
- Insiders · 12m
- 8 distinct reporters
- 10b5-1 share
- 97% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | Megna Michael RCHIEF ACCOUNTING OFFICER · O | ▼ Sale | 4,600 | $80.3 | $369K | -13.7% | plan |
| Jul 29, 2026 | Cole G BradleyD | ▼ Sale | 3,673 | $81.43 | $299K | -23.9% | — |
| May 1, 2026 | Paolini John F.CHIEF MEDICAL OFFICER · O | ▼ Sale | 58,424 | $53.71 | $3.1M | -47.1% | plan · 2 tranches |
| May 1, 2026 | Patel Sanj KCHAIRMAN & CEO · O·D | ▼ Sale | 48,565 | $54.02 | $2.6M | -100% | plan |
| Apr 30, 2026 | Patel Sanj KCHAIRMAN & CEO · O·D | ▼ Sale | 508,339 | $51.96 | $26.4M | -100% | plan · 6 tranches |
| Apr 28, 2026 | Quart Barry DD | ▼ Sale | 13,099 | $50.1 | $656K | -51.1% | plan |
| Apr 9, 2026 | Moat RossCHIEF OPERATING OFFICER · O | ▼ Sale | 1,703 | $46.69 | $80K | -12.4% | plan |
| Apr 9, 2026 | Megna Michael RCHIEF ACCOUNTING OFFICER · O | ▼ Sale | 6,625 | $46.69 | $309K | -19.5% | plan |
| Apr 6, 2026 | Moat RossCHIEF OPERATING OFFICER · O | ▼ Sale | 2,367 | $48.58 | $115K | -16.4% | plan |
| Apr 6, 2026 | Patel Sanj KCHAIRMAN & CEO · O·D | ▼ Sale | 7,278 | $50.01 | $364K | -100% | plan |
| Apr 6, 2026 | Quart Barry DD | ▼ Sale | 6,901 | $50 | $345K | -35.5% | plan |
| Mar 9, 2026 | Ragosa MarkCHIEF FINANCIAL OFFICER · O | ▼ Sale | 36,722 | $45.92 | $1.7M | -75.2% | plan · 2 tranches |
| Mar 2, 2026 | Paolini John F.CHIEF MEDICAL OFFICER · O | ▼ Sale | 40,000 | $44.82 | $1.8M | -39.5% | plan · 3 tranches |
| Feb 12, 2026 | Quart Barry DD | ▼ Sale | 2,800 | $45 | $126K | -18.2% | plan · 2 tranches |
| Feb 9, 2026 | Ragosa MarkCHIEF FINANCIAL OFFICER · O | ▼ Sale | 17,845 | $43.28 | $772K | -59.6% | plan · 2 tranches |
| Feb 4, 2026 | Quart Barry DD | ▼ Sale | 15,960 | $45.22 | $722K | -56% | plan · 3 tranches |
| Jan 8, 2026 | Ragosa MarkCHIEF FINANCIAL OFFICER · O | ▼ Sale | 12,000 | $41.89 | $503K | -38.6% | plan |
| Dec 15, 2025 | Tessari EbenCHIEF OPERATING OFFICER · O | ▼ Sale | 12,048 | $41.56 | $501K | -42% | plan |
| Dec 15, 2025 | Quart Barry DD | ▼ Sale | 20,129 | $41.51 | $836K | -61.6% | plan |
| Dec 8, 2025 | Ragosa MarkCHIEF FINANCIAL OFFICER · O | ▼ Sale | 42,841 | $41.49 | $1.8M | -58% | plan |
| Nov 26, 2025 | Tessari EbenCHIEF OPERATING OFFICER · O | ▼ Sale | 200 | $42.89 | $9K | -0.9% | plan |
| Nov 17, 2025 | Tessari EbenCHIEF OPERATING OFFICER · O | ▼ Sale | 12,470 | $41.24 | $514K | -35.4% | plan · 2 tranches |
| Nov 12, 2025 | Ragosa MarkCHIEF FINANCIAL OFFICER · O | ▼ Sale | 19,900 | $40.94 | $815K | -39% | plan |
| Oct 31, 2025 | Paolini John F.CHIEF MEDICAL OFFICER · O | ▼ Sale | 82,542 | $37.14 | $3.1M | -57.4% | plan |
| Oct 28, 2025 | Ragosa MarkCHIEF FINANCIAL OFFICER · O | ▼ Sale | 100 | $41 | $4K | -0.3% | plan |
| Oct 22, 2025 | Patel Sanj KCHAIRMAN & CEO · O·D | ▼ Sale | 257,969 | $38.86 | $10.0M | -69.8% | plan · 4 tranches |
| Oct 20, 2025 | Megna Michael RCHIEF ACCOUNTING OFFICER · O | ▼ Sale | 50,490 | $38.87 | $2.0M | -65.1% | plan · 2 tranches |
| Oct 14, 2025 | Tessari EbenCHIEF OPERATING OFFICER · O | ▼ Sale | 12,368 | $37.67 | $466K | -30.1% | plan · 2 tranches |
| Sep 29, 2025 | Tessari EbenCHIEF OPERATING OFFICER · O | ▼ Sale | 42,000 | $38.33 | $1.6M | -54.9% | plan |
| Sep 15, 2025 | Tessari EbenCHIEF OPERATING OFFICER · O | ▼ Sale | 16,400 | $36.46 | $598K | -32.2% | plan · 2 tranches |
| Sep 5, 2025 | Tessari EbenCHIEF OPERATING OFFICER · O | ▼ Sale | 98,660 | $35.54 | $3.5M | -68.9% | plan · 2 tranches |
| Sep 4, 2025 | Moat RossCHIEF CORP. & COMM. OFFICER · O | ▼ Sale | 3,523 | $35.31 | $124K | -27.2% | plan |
| Sep 3, 2025 | Tessari EbenCHIEF OPERATING OFFICER · O | ▼ Sale | 15,091 | $35.5 | $536K | -25.3% | plan |
| Sep 3, 2025 | Megna Michael RCHIEF ACCOUNTING OFFICER · O | ▼ Sale | 11,000 | $34.84 | $383K | -22.4% | plan |
| Aug 18, 2025 | Tessari EbenCHIEF OPERATING OFFICER · O | ▼ Sale | 16,200 | $33.77 | $547K | -28.7% | plan · 2 tranches |
| Aug 14, 2025 | Malley ThomasD | ▼ Sale | 177,769 | $32.96 | $5.9M | -93.4% | 3 tranches |
Every $KNSA filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Kiniksa Pharmaceuticals International filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $KNSA feed.